MX2021003450A - Metodos para tratar trastornos mieloproliferativos. - Google Patents
Metodos para tratar trastornos mieloproliferativos.Info
- Publication number
- MX2021003450A MX2021003450A MX2021003450A MX2021003450A MX2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- myeloproliferative disorders
- treating myeloproliferative
- treating
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736369P | 2018-09-25 | 2018-09-25 | |
| US201862783076P | 2018-12-20 | 2018-12-20 | |
| PCT/US2019/052608 WO2020068755A1 (en) | 2018-09-25 | 2019-09-24 | Methods of treating myeloproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003450A true MX2021003450A (es) | 2021-07-16 |
Family
ID=69950867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003450A MX2021003450A (es) | 2018-09-25 | 2019-09-24 | Metodos para tratar trastornos mieloproliferativos. |
| MX2023013844A MX2023013844A (es) | 2018-09-25 | 2021-03-24 | Metodos para tratar trastornos mieloproliferativos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013844A MX2023013844A (es) | 2018-09-25 | 2021-03-24 | Metodos para tratar trastornos mieloproliferativos. |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| MA53745A (fr) * | 2018-09-25 | 2021-08-04 | Impact Biomedicines Inc | Procédés de traitement de troubles myéloprolifératifs |
| MY209349A (en) | 2018-09-25 | 2025-07-03 | Impact Biomedicines Inc | Methods of treating myeloproliferative disorders |
| US12559463B2 (en) | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
| EP4262770A1 (en) * | 2020-12-16 | 2023-10-25 | Impact Biomedicines, Inc. | Dosing of fedratinib |
| EP4297750A1 (en) | 2021-02-25 | 2024-01-03 | Impact Biomedicines, Inc. | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
| US20240358722A1 (en) * | 2021-09-14 | 2024-10-31 | Impact Biomedicines, Inc. | Methods of administering fedratinib |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007053452A1 (en) * | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US20090093009A1 (en) * | 2007-10-09 | 2009-04-09 | Sum Chan | Mass spectrometry method for measuring thiamine in body fluid |
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US20130102624A1 (en) * | 2011-05-19 | 2013-04-25 | John V. Schloss | Early detection of thiamine deficiency |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| WO2015081127A2 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| MX2016009974A (es) * | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| WO2017024171A1 (en) * | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| MA53745A (fr) | 2018-09-25 | 2021-08-04 | Impact Biomedicines Inc | Procédés de traitement de troubles myéloprolifératifs |
| MY209349A (en) | 2018-09-25 | 2025-07-03 | Impact Biomedicines Inc | Methods of treating myeloproliferative disorders |
| US12559463B2 (en) | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
| FR3092581A1 (fr) | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
-
2019
- 2019-09-24 MY MYPI2021001641A patent/MY209349A/en unknown
- 2019-09-24 WO PCT/US2019/052608 patent/WO2020068755A1/en not_active Ceased
- 2019-09-24 JP JP2021540380A patent/JP7856429B2/ja active Active
- 2019-09-24 US US17/279,765 patent/US20220031699A1/en not_active Abandoned
- 2019-09-24 EP EP19866319.7A patent/EP3856169A4/en active Pending
- 2019-09-24 MX MX2021003450A patent/MX2021003450A/es unknown
- 2019-09-24 CN CN201980070403.4A patent/CN113286584A/zh active Pending
- 2019-09-24 KR KR1020217012234A patent/KR20210102192A/ko not_active Ceased
- 2019-09-24 KR KR1020257037570A patent/KR20250164332A/ko active Pending
- 2019-09-24 MA MA053741A patent/MA53741A/fr unknown
- 2019-09-24 SG SG11202103019WA patent/SG11202103019WA/en unknown
- 2019-09-24 BR BR112021005518-5A patent/BR112021005518A2/pt unknown
- 2019-09-24 AU AU2019346521A patent/AU2019346521B2/en active Active
-
2021
- 2021-03-22 IL IL281736A patent/IL281736A/en unknown
- 2021-03-24 MX MX2023013844A patent/MX2023013844A/es unknown
- 2021-03-25 CL CL2021000744A patent/CL2021000744A1/es unknown
- 2021-12-23 US US17/560,373 patent/US11400092B2/en active Active
-
2024
- 2024-08-01 JP JP2024125670A patent/JP2024161416A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220031699A1 (en) | 2022-02-03 |
| CL2021000744A1 (es) | 2021-10-08 |
| JP2022502492A (ja) | 2022-01-11 |
| AU2019346521B2 (en) | 2025-05-08 |
| US20220133724A1 (en) | 2022-05-05 |
| BR112021005518A2 (pt) | 2021-06-29 |
| JP2024161416A (ja) | 2024-11-19 |
| MA53741A (fr) | 2021-08-04 |
| IL281736A (en) | 2021-05-31 |
| MX2023013844A (es) | 2023-12-08 |
| JP7856429B2 (ja) | 2026-05-11 |
| KR20250164332A (ko) | 2025-11-24 |
| WO2020068755A1 (en) | 2020-04-02 |
| KR20210102192A (ko) | 2021-08-19 |
| US11400092B2 (en) | 2022-08-02 |
| AU2019346521A1 (en) | 2021-05-20 |
| EP3856169A4 (en) | 2022-06-29 |
| MY209349A (en) | 2025-07-03 |
| CN113286584A (zh) | 2021-08-20 |
| SG11202103019WA (en) | 2021-04-29 |
| EP3856169A1 (en) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000744A1 (es) | Métodos para tratar trastornos mieloproliferativos | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| MX2021010198A (es) | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| CO2018012946A2 (es) | Moduladores de la vía de estrés integrada | |
| CR20170011A (es) | Compuestos de heteroarilo para la inhibición de cinasa | |
| MX377141B (es) | Composiciones y metodos para modular la expresion de pkk. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| UY36716A (es) | Moduladores de receptores nucleares | |
| MX2018000778A (es) | Metodos para tratar trastornos mediados por hepcidinas. | |
| MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| MX2020002435A (es) | Agentes que modulan las funciones de beta-catenina y sus métodos. | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| JOP20220042A1 (ar) | طرق لعلاج فرط فينيل ألانين الدم | |
| MX386146B (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| BR112017025263A2 (pt) | método para o tratamento de doença neurológica | |
| SG11202105279SA (en) | Methods of treating myeloproliferative disorders | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| MX2022013383A (es) | Composiciones y metodo para tratar la depresion. | |
| GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| EP3856189A4 (en) | Methods of treating myeloproliferative disorders | |
| MX374705B (es) | Composiciones que comprenden anakinra. |